美股新聞 標題聯播 · 近 24 小時 336 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · TARS近 30 天 2 則 · 第 1 / 1 頁
- 何時拋售股票：這 BD 5 分股觸發賣出訊號When To Dump Stocks: These IBD 50 Components Hit Sell Signals
- Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
- Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak
- Tarsus joins Stargardt race to market with $800m Alkeus takeover
- Tarsus Pharmaceuticals Inc (TARS) (Q2 2026) Earnings Call Highlights: Record XDEMVY Sales and ...
- Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M
- Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
- Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
- Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
- Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
- Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
- Tarsus Pharmaceuticals (TARS) Replaces Its Commercial Chief While iRenix Talks Continue
- Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。